Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.

Marcia L. Taylor, Dean D. Metcalfe, Kit signal transduction. Hematology-oncology Clinics of North America. ,vol. 14, pp. 517- 535 ,(2000) , 10.1016/S0889-8588(05)70294-X

Tony Hunter, Bartholomew M. Sefton, Transforming gene product of Rous sarcoma virus phosphorylates tyrosine Proceedings of the National Academy of Sciences of the United States of America. ,vol. 77, pp. 1311- 1315 ,(1980) , 10.1073/PNAS.77.3.1311

Mihnea V. Chiorean, Maria Eugenia Guicciardi, Jung-Hwan Yoon, Steven F. Bronk, Scott H. Kaufmanns, Gregory J. Gores, Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells Liver International. ,vol. 24, pp. 687- 695 ,(2004) , 10.1111/J.1478-3231.2004.0984.X

Christopher D.M. Fletcher, Heikki Joensuu, George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter J. Roberts, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra L. Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Sasa Dimitrijevic, Brian J. Druker, Christopher Corless, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. ,vol. 347, pp. 472- 480 ,(2002) , 10.1056/NEJMOA020461

Brian J. Druker, Shu Tamura, Elisabeth Buchdunger, Sayuri Ohno, Gerald M. Segal, Shane Fanning, Jürg Zimmermann, Nicholas B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine. ,vol. 2, pp. 561- 566 ,(1996) , 10.1038/NM0596-561

F. Eckel, S. von Delius, M. Mayr, M. Dobritz, F. Fend, C. Hosius, E. Schleyer, E. Schulte-Frohlinde, R.M. Schmid, C. Lersch, Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology. ,vol. 69, pp. 363- 371 ,(2005) , 10.1159/000089990

Mark A. Lemmon, Joseph Schlessinger, Cell signaling by receptor-tyrosine kinases Cell. ,vol. 141, pp. 1117- 1134 ,(2000) , 10.1016/J.CELL.2010.06.011

David G. Savage, Karen H. Antman, Imatinib Mesylate — A New Oral Targeted Therapy The New England Journal of Medicine. ,vol. 346, pp. 683- 693 ,(2002) , 10.1056/NEJMRA013339

O Uziel, E Fenig, J Nordenberg, E Beery, H Reshef, J Sandbank, M Birenbaum, M Bakhanashvili, R Yerushalmi, D Luria, M Lahav, Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines British Journal of Cancer. ,vol. 92, pp. 1881- 1891 ,(2005) , 10.1038/SJ.BJC.6602592

RuJu Chian, Sonia Young, Alla Danilkovitch-Miagkova, Lars Rönnstrand, Edward Leonard, Petranel Ferrao, Leonie Ashman, Diana Linnekin, Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood. ,vol. 98, pp. 1365- 1373 ,(2001) , 10.1182/BLOOD.V98.5.1365